Pharmacoeconomic analyses: whose perspective counts and costs the most?
- PMID: 8092157
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Comment in
-
Cost-effectiveness, not cost containment.Am J Hosp Pharm. 1994 Jun 15;51(12):1569-71. Am J Hosp Pharm. 1994. PMID: 8092158 No abstract available.
Comment on
-
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.Am J Hosp Pharm. 1994 Jun 15;51(12):1555-63. Am J Hosp Pharm. 1994. PMID: 8092156